

## Special Issue

# Vaccines for COVID-19

### Message from the Guest Editors

Three years after the spread of SARS-CoV-2, the virus responsible for the last global pandemic event, we can take stock of the past, present, and future of the SARS-CoV-2 virus. This includes, on one hand, the about 7 million deaths around the world caused by the virus (though this number could be an underestimation), but also, on the other, the vast range of pharmacological measures and vaccine options that did not exist in 2020. Because of the pandemic, health systems globally bordered on collapse, having to deal with extreme numbers of simultaneous cases. The situation today is far more manageable, though the virus continues to circulate and remains challenging to eradicate. The topics that I invite you to reflect on are as follows:

- The impact of vaccination on the general population;
- The impact of vaccination on the elderly population;
- The impact of vaccination on the population of so-called fragile subjects (immunosuppressed, sick, those with oncological problems or heart disease, etc.).

---

### Guest Editors

Dr. Filippo Luciani

Infectious Diseases Unit of Annunziata Hospital, 87100 Cosenza, Italy

Dr. Erika Cione

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy

---

### Deadline for manuscript submissions

closed (7 October 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/162058](https://mdpi.com/si/162058)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).